bivalirudin / Generic mfg. - LARVOL DELTA

Perioperative Management of Immune Thrombocytopenic Purpura in Cardiac Surgery: A Systematic Review of the Literature in Urgent and Elective Settings. (PubMed, Cureus) - "Reported management approaches centered on rapid immunomodulation with intravenous immunoglobulin and/or corticosteroids, selective adjunctive platelet transfusion, antifibrinolytic therapy, thrombopoietin receptor agonists in selected cases, and carefully monitored cardiopulmonary bypass anticoagulation, most commonly using unfractionated heparin with activated clotting time guidance; bivalirudin was described in isolated reports. Across studies, perioperative bleeding occurred in approximately 32% of patients, platelet transfusion in 45%, reoperation for bleeding in 8%, thrombotic complications in 6%, and perioperative mortality in 7%, with consistently inferior outcomes observed in urgent and emergent procedures. Although the evidence base remains largely case-derived and heterogeneous, these data support a coherent multimodal perioperative strategy integrating rapid platelet-directed immunotherapy, patient blood management-guided hemostasis, antifibrinolytic use, and..."

Journal • Review • Cardiovascular • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Thrombocytopenia • Thrombocytopenic Purpura

Argatroban Anticoagulation for Heparin Induced Thrombocytopenia After Heartmate 3 Implantation: A Case Series. (PubMed, Transplant Proc) - "Argatroban appears to be an effective and safe alternative anticoagulant for HIT after LVAD implantation, enabling platelet recovery without a significant increase in bleeding or thrombotic events. Differentiating complications attributable to HIT or argatroban from those inherent to LVAD support remains challenging, given the device's intrinsic risks of thrombosis, bleeding, and mortality."

Journal • Cardiovascular • Hematological Disorders • Immunology • Infectious Disease • Inflammatory Arthritis • Metabolic Disorders • Pneumonia • Respiratory Diseases • Septic Shock • Thrombocytopenia • Thrombosis

BRIGHT-HBR: Bivalirudin Versus Heparin During PCI in High Bleeding Risk Patients With Acute Coronary Syndromes (clinicaltrials.gov) - P4 | N=5270 | Not yet recruiting | Sponsor: Shenyang Northern Hospital

New P4 trial • Acute Coronary Syndrome • Cardiovascular

Variation in Bivalirudin Requirements for Children with Ventricular Assist Devices (ISHLT 2026) - "Abstract is embargoed at this time."

Clinical • Pediatrics

Investigating Variation in APTT Levels Between Different IV Access Techniques in Pediatric Patients Receiving Bivalirudin for Ventricular Assistive Device Therapy (ISHLT 2026) - "Abstract is embargoed at this time."

Clinical • Pediatrics

Clinical Experience Using Drug-Calibrated Dilute Thrombin Time for Monitoring Bivalirudin in Pediatric Ventricular Assist Devices (ISHLT 2026) - "Abstract is embargoed at this time."

Clinical • Pediatrics

Nitric oxide in the ECMO circuit as a treatment option for heparin-induced thrombocytopenia: A case report. (PubMed, Perfusion) - "This intricate, self-reinforcing process results in a prothrombotic state, predisposing patients to arterial, venous, or oxygenator thrombosis. Unfractionated heparin is the standard anticoagulant chosen in ECMO patients to prevent such complications.Case ReportIn this case report our patient presented heparin-induced thrombocytopenia (HIT), a possible complication.DiscussionAlternative strategies such as bivalirudin and argatroban are possible options but due the unavailability of those medications at our institution, nitric oxide (NO) via sweep-gas flow was deemed a reasonable alternative considering it's anti-aggregant effect.ConclusionThis case report details the use of NO as a possible alternative anticoagulant strategy in a patient with ECMO complicated by HIT."

Journal • Cardiovascular • Hematological Disorders • Thrombocytopenia • Thrombosis • Transplantation

Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System (clinicaltrials.gov) - P2 | N=50 | Recruiting | Sponsor: Stanford University | Enrolling by invitation ➔ Recruiting | Phase classification: PN/A ➔ P2 | Trial completion date: Sep 2027 ➔ Sep 2029 | Trial primary completion date: Sep 2026 ➔ Sep 2027

Enrollment status • Phase classification • Trial completion date • Trial primary completion date • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure

COMPARISON OF BIVALIRUDIN VERSUS HEPARIN IN PATIENTS WITH PERCUTANEOUS VENTRICULAR ASSIST DEVICE SUPPORT (ACC 2026) - "Abstract is embargoed at this time."

Clinical

CHROMOGENIC FACTOR X VS INTERNATIONAL NORMALIZED RATIO MONITORING IN PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA TRANSITIONED FROM BIVALIRUDIN TO WARFARIN (ACC 2026) - "Abstract is embargoed at this time."

Clinical • Hematological Disorders • Thrombocytopenia

EFFICACY AND SAFETY OF ANTICOAGULATION WITH BIVALIRUDIN VERSUS UNFRACTIONATED HEPARIN IN PATIENTS ON EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) (ACC 2026) - "Abstract is embargoed at this time."

Clinical

COMPARING OUTCOMES BETWEEN HEPARIN AND BIVALIRUDIN USE IN CARDIOGENIC SHOCK PATIENTS ON LEFT VENTRICLE ASSIST DEVICES: A PROPENSITY-MATCHED REAL-WORLD STUDY (ACC 2026) - "Abstract is embargoed at this time."

Clinical • Real-world • Real-world evidence • Cardiovascular

BIVALIRUDIN VERSUS HEPARIN FOR ANTICOAGULATION IN ADULT ECMO: AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS INCORPORATING SENSITIVITY ANALYSES, PUBLICATION BIAS ASSESSMENT, AND GRADE EVALUATION (ACC 2026) - "Abstract is embargoed at this time."

Retrospective data • Review

HEPARIN VS BIVALIRUDIN IN AMI-CARDIOGENIC SHOCK SUPPORTED WITH PERCUTANEOUS LEFT VENTRICLE ASSIST DEVICES: A PROPENSITY-MATCHED REAL-WORLD STUDY (ACC 2026) - "Abstract is embargoed at this time."

Clinical • Real-world • Real-world evidence • Cardiovascular

Prognostic Implications of Evolving Universal Definitions of Periprocedural Myocardial Infarction in Patients With Acute Coronary Syndrome. (PubMed, Circulation) - P3 | "The objective of this study was to compare prognostic implications of evolving universal definitions of PCI-MI in a large cohort of patients with ACS from the MATRIX trial (Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of AngioX)...These data support the evolution of the universal definition of PCI-MI. URL: http://www.clinicaltrials.gov; Unique identifier: NCT01433627."

Journal • Acute Coronary Syndrome • Cardiovascular • Myocardial Infarction

Heparin Resistance in Cardiac Surgery with Cardiopulmonary Bypass: Mechanisms, Clinical Implications, and Evidence-Based Management. (PubMed, Medicina (Kaunas)) - "Pre-bypass risk assessment, multimodal monitoring, and an algorithm prioritizing UFH optimization, AT repletion, and timely use of direct thrombin inhibitors provide a pragmatic framework to limit thrombosis and bleeding. Harmonized definitions and comparative trials remain priorities."

Journal • Review • Cardiovascular • Genetic Disorders • Hematological Disorders • Infectious Disease • Inflammation • Obesity • Septic Shock • Thrombocytosis • Thrombosis

Staged mechanical circulatory support in paediatric HIT: Bivalirudin anticoagulation across ECMO, VAD, and cardiac transplantation. (PubMed, Perfusion) - "The bivalirudin protocols allowed safe progression through all three phases.ConclusionBivalirudin strategy provided safe, effective antithrombotic management across ECMO, VAD implantation, and heart transplantation in a paediatric patient with HIT. Monitoring its effectiveness at higher anticoagulation levels remains challenging, and patients may require higher doses to achieve desired endpoints."

Journal • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • Hematological Disorders • Pediatrics • Thrombocytopenia • Thrombosis • Transplantation

Avoiding the Vicious Cycle: Successful Extracorporeal Membrane Oxygenation Weaning via Serratus Anterior Plane Block for Postthoracotomy Pain: A Case Report. (PubMed, A A Pract) - "We present the case of a patient on bivalirudin after undergoing a thoracotomy for a right lung transplantation. This case highlights the successful use of a serratus anterior plane block (SAPB) as an alternative approach to neuraxial anesthesia in an anticoagulated patient, optimizing analgesia and facilitating recovery postthoracotomy."

Journal • Anesthesia • Hematological Disorders • Pain • Transplantation

Comparison of Heparin vs Bivalirudin Therapy for Anticoagulation in Patients Receiving Extracorporeal Membrane Oxygenation (ASHP 2025) - No abstract available

Clinical

Efficacy and Safety of Bivalirudin in Patients on Extracorporeal Membrane Oxygenation (ECMO) (ASHP 2025) - No abstract available

Clinical

Bye-Bye-Bivalirudin (ASHP 2025) - No abstract available

Argatroban Versus Bivalirudin for Heparin-Induced Thrombocytopenia in Critically Ill Adults (ASHP 2025) - No abstract available

Clinical • Hematological Disorders • Thrombocytopenia

Safety and Efficacy of Bivalirudin in Patients Receiving Extracorporeal Membrane Oxygenation (ASHP 2025) - No abstract available

Clinical

Evaluation of Argatroban and Bivalirudin Use in Patients with Suspected Heparin-Induced Thrombocytopenia (HIT) (ASHP 2025) - No abstract available

Clinical • Hematological Disorders • Thrombocytopenia

Use of Bivalirudin Versus Argatroban Drip in Continuous Renal Replacement Therapy Patients (ASHP 2025) - No abstract available

Clinical